Anaptysbio Inc (ANAB) Stock Price, Quote & News

Company Profile

AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared co...

Industry: Biotechnology

Sector: Healthcare

Phone: 858 362 6295

Website: www.anaptysbio.com

Address:

10770 Wateridge Circle, Suite 210, San Diego, United States

StockBraker Dec. 30 at 8:18 PM

$ANAB Rebuying the $52's I sold the other day.

0 · Reply

StockBraker Dec. 29 at 3:48 PM

$ANAB Another new high this morning. https://au.investing.com/news/company-news/anaptysbio-stock-hits-52week-high-at-5158-93CH-4185552

1 · Reply

StockBraker Dec. 29 at 3:04 PM

$ANAB $51.78 this morning. Another 52 week high. Personally HODLing for $65.

0 · Reply

CastleCube Dec. 26 at 4:24 AM

$ANAB What matters next is the company’s ability to build a predictable delivery rhythm. Sequential improvement must start appearing across core metrics. Momentum becomes sustainable only with dependable execution. The next phase will be defined less by vision and more by delivery.

2 · Reply

StockBraker Dec. 22 at 5:53 PM

$ANAB Another 52 week high today.

0 · Reply

StockBraker Dec. 22 at 5:31 PM

$ANAB Minimal downside, plenty of upside.

0 · Reply

UgoGreg Dec. 20 at 5:59 PM

$ANAB https://youtu.be/ygBN8MilTyc

0 · Reply

StockBraker Dec. 19 at 8:00 PM

$ANAB Yatin is bananas 🍌🍌, but I love 😻him nonetheless.

0 · Reply

StockBraker Dec. 19 at 3:35 PM

$ANAB Congrats all. A new 52 week high set again today.

0 · Reply

JarvisFlow Dec. 17 at 5:46 PM

Barclays has adjusted their stance on AnaptysBio ( $ANAB ), setting the rating to Overweight with a target price of 70 → 55.

0 · Reply

Vanda Announces Submission of Biologics License Application to the FDA for Imsidolimab for the Treatment of Generalized Pustular Psoriasis

VNDA

Nov 25, 2025, 4:15 PM EST - 5 weeks ago

Anaptys Announces Participation in December Investor Conferences

Nov 21, 2025, 8:52 AM EST - 5 weeks ago

AnaptysBio shares tumble after legal fight with GSK over cancer drug license

GSK

Nov 21, 2025, 8:48 AM EST - 5 weeks ago

GSK Unit Tesaro Sues AnaptysBio, Threatening Key Cancer Drug Jemperli Royalties

GSK

Nov 21, 2025, 6:14 AM EST - 5 weeks ago

GSK, AnaptysBio Sue Each Other Over Cancer Drug License

GSK

Nov 21, 2025, 4:00 AM EST - 5 weeks ago

Anaptys Announces $100 Million Stock Repurchase Plan

Nov 21, 2025, 3:50 AM EST - 5 weeks ago

Anaptys Initiates Litigation Against Tesaro, a GSK Subsidiary

GSK

Nov 13, 2025, 7:30 AM EST - 6 weeks ago

AnaptysBio: Maintaining 'Hold' As RA Program Still In Play With ANB033 Advancement

Nov 10, 2025, 12:30 PM EST - 7 weeks ago

AnaptysBio To Save $10 Million After Discontinuing Ulcerative Colitis Study

Nov 10, 2025, 9:00 AM EST - 7 weeks ago

Anaptys Announces Phase 2 Trial of Rosnilimab Did Not Meet Primary or Secondary Endpoints at Week 12 in Moderate-to-Severe Ulcerative Colitis

Nov 4, 2025, 4:15 PM EST - 2 months ago

Anaptys Announces Third Quarter 2025 Financial Results and Provides Business Update

Nov 4, 2025, 4:15 PM EST - 2 months ago

Anaptys Announces Participation in November Investor Conferences

Oct 29, 2025, 9:15 AM EDT - 2 months ago

Anaptys Announces New Positive Phase 2b Trial Results for Rosnilimab in Rheumatoid Arthritis at ACR Late-Breaking Oral Presentation

Oct 15, 2025, 5:37 AM EDT - 2 months ago

AnaptysBio, Inc. - Special Call

Oct 13, 2025, 9:15 AM EDT - 2 months ago

Anaptys Announces Late-Breaking Oral Presentation of Complete Phase 2b Data for Rosnilimab in Rheumatoid Arthritis at Upcoming ACR Convergence 2025

Sep 30, 2025, 1:59 PM EDT - 3 months ago

AnaptysBio Charts Path To Split Into Two Public Companies By 2026

Sep 29, 2025, 4:05 PM EDT - 3 months ago

Anaptys Announces Intent to Separate Biopharma Operations from Substantial Royalty Assets by Year-end 2026

Sep 29, 2025, 4:05 PM EDT - 3 months ago

Anaptys to Provide Overview of ANB033, a CD122 antagonist, at Virtual Investor Event on Tuesday, Oct. 14

Aug 27, 2025, 4:15 PM EDT - 4 months ago

Anaptys Announces Participation in September Investor Conferences

Aug 6, 2025, 4:15 PM EDT - 5 months ago

Anaptys Announces Second Quarter 2025 Financial Results and Provides Business Update

Jun 10, 2025, 1:33 PM EDT - 7 months ago

AnaptysBio: Rosnilimab's RA Data Sets The Stage For Blockbuster Potential

Jun 6, 2025, 3:39 PM EDT - 7 months ago

AnaptysBio: Positive RA Data Bodes Well For Continued Rosnilimab Advancement

Jun 4, 2025, 2:23 PM EDT - 7 months ago

AnaptysBio's Arthritis Drug Matches Top Therapies In Phase 2 Trial, Analyst Sees Turning Point

Jun 3, 2025, 4:05 PM EDT - 7 months ago

Anaptys Announces Positive Rosnilimab Data Updated Through Six Months in Robust Phase 2b Trial in RA

May 27, 2025, 4:15 PM EDT - 7 months ago

Anaptys to Announce Updated Data from Phase 2b Trial of Rosnilimab, a PD-1 Depleter and Agonist, for Rheumatoid Arthritis on June 3, 2025

May 5, 2025, 4:15 PM EDT - 8 months ago

Anaptys Announces First Quarter 2025 Financial Results and Provides Business Update

Mar 24, 2025, 9:15 AM EDT - 10 months ago

Anaptys Announces Stock Repurchase Plan

Feb 27, 2025, 4:15 PM EST - 10 months ago

Anaptys Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Feb 27, 2025, 4:15 PM EST - 10 months ago

Anaptys Announces Participation in March Investor Conferences

Feb 12, 2025, 7:30 AM EST - 11 months ago

Anaptys Announces Rosnilimab Achieved Positive Results in RA Phase 2b Trial and Highest Ever Reported CDAI LDA Response Over 6 Months

Feb 11, 2025, 5:30 PM EST - 11 months ago

Anaptys to Announce Top-line Data from Phase 2b Trial of Rosnilimab, a PD-1 Depleter and Agonist, in Rheumatoid Arthritis on Feb. 12, 2025

Feb 3, 2025, 4:15 PM EST - 11 months ago

Anaptys to Present at the Guggenheim SMID Cap Biotech Conference

Feb 3, 2025, 7:30 AM EST - 11 months ago

Vanda Pharmaceuticals and Anaptys Announce Exclusive Global License Agreement for Vanda to Develop and Commercialize Imsidolimab, an IL-36R Antagonist

Jan 7, 2025, 9:15 AM EST - 1 year ago

Anaptys to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Dec 11, 2024, 2:07 PM EST - 1 year ago

AnaptysBio Discontinues Investment In Eczema Candidate After Disappointing Data

Dec 11, 2024, 10:20 AM EST - 1 year ago

AnaptysBio to abandon eczema drug development after mid-stage trial failure

Dec 11, 2024, 8:42 AM EST - 1 year ago

AnaptysBio abandons eczema drug development after mid-stage trial failure

Dec 11, 2024, 8:30 AM EST - 1 year ago

Anaptys Announces Phase 2b Trial of ANB032, a BTLA Agonist, Did Not Meet Primary or Secondary Endpoints in Atopic Dermatitis

Nov 5, 2024, 4:15 PM EST - 1 year ago

Anaptys Announces Participation in November and December Investor Conferences

Nov 5, 2024, 4:15 PM EST - 1 year ago

Anaptys Announces Third Quarter 2024 Financial Results and Provides Business Update

Aug 15, 2024, 2:14 PM EDT - 1 year ago

AnaptysBio: Top-Line AD Data End Of 2024 Could Be Turning Point

Aug 14, 2024, 5:00 AM EDT - 1 year ago

Anaptys Announces Pricing of $100 Million Underwritten Registered Direct Offering

Aug 5, 2024, 4:15 PM EDT - 1 year ago

Anaptys Announces Second Quarter 2024 Financial Results and Provides Business Update

Jul 22, 2024, 2:53 PM EDT - 1 year ago

AnaptysBio Investigational Arthritis Drug Might Have Better Efficacy Profile Than Eli Lilly's: Analyst

May 9, 2024, 4:15 PM EDT - 1 year ago

Anaptys Announces First Quarter 2024 Financial Results and Provides Business Update

May 9, 2024, 4:10 PM EDT - 1 year ago

Anaptys Announces Positive Top-Line GEMINI-2 Phase 3 Clinical Trial Results of Imsidolimab (IL-36R) in Generalized Pustular Psoriasis (GPP)

May 9, 2024, 4:05 PM EDT - 1 year ago

Anaptys to Receive $50 Million in a Capped Non-Recourse Monetization from Amended Agreement with Sagard in Exchange for Additional Jemperli Royalties

Apr 24, 2024, 9:00 AM EDT - 1 year ago

Actym Therapeutics Appoints Thomas Smart as CEO

PGEN XOMA

Mar 11, 2024, 4:15 PM EDT - 1 year ago

Anaptys Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Feb 29, 2024, 9:15 AM EST - 1 year ago

Anaptys to Present at TD Cowen's 44th Annual Health Care Conference and 2024 AAD Annual Meeting

StockBraker Dec. 30 at 8:18 PM

$ANAB Rebuying the $52's I sold the other day.

0 · Reply

StockBraker Dec. 29 at 3:48 PM

$ANAB Another new high this morning. https://au.investing.com/news/company-news/anaptysbio-stock-hits-52week-high-at-5158-93CH-4185552

1 · Reply

StockBraker Dec. 29 at 3:04 PM

$ANAB $51.78 this morning. Another 52 week high. Personally HODLing for $65.

0 · Reply

CastleCube Dec. 26 at 4:24 AM

2 · Reply

StockBraker Dec. 22 at 5:53 PM

$ANAB Another 52 week high today.

0 · Reply

StockBraker Dec. 22 at 5:31 PM

$ANAB Minimal downside, plenty of upside.

0 · Reply

UgoGreg Dec. 20 at 5:59 PM

$ANAB https://youtu.be/ygBN8MilTyc

0 · Reply

StockBraker Dec. 19 at 8:00 PM

$ANAB Yatin is bananas 🍌🍌, but I love 😻him nonetheless.

0 · Reply

StockBraker Dec. 19 at 3:35 PM

$ANAB Congrats all. A new 52 week high set again today.

0 · Reply

JarvisFlow Dec. 17 at 5:46 PM

Barclays has adjusted their stance on AnaptysBio ( $ANAB ), setting the rating to Overweight with a target price of 70 → 55.

0 · Reply

StockBraker Dec. 17 at 1:37 PM

$ANAB

1 · Reply

StockBraker Dec. 11 at 6:45 PM

$ANAB New 52 week high reached.

0 · Reply

StockBraker Dec. 11 at 5:00 PM

$ANAB Revisiting my rather crude analysis chart from mid-July. We took a bit of a steep upward turn in late August. Hoping the new channel holds.

0 · Reply

Reanimated666 Dec. 11 at 4:35 PM

$ANAB 56 price target Stifel

0 · Reply

anachartanalyst Dec. 11 at 2:39 PM

$ANAB https://anachart.com/wp-content/uploads/ana_temp/1765463959_soc-img.jpg

0 · Reply

JarvisFlow Dec. 11 at 1:17 PM

Stifel has updated their rating for AnaptysBio ( $ANAB ) to Buy with a price target of 56.

0 · Reply

StockBraker Dec. 10 at 10:34 PM

$ANAB

0 · Reply

StockBraker Dec. 3 at 9:50 PM

$ANAB https://www.investing.com/news/company-news/anaptysbio-stock-hits-52week-high-at-4335-usd-93CH-4389213

0 · Reply

Reanimated666 Dec. 3 at 8:54 PM

$ANAB Higher Highs

0 · Reply

Reanimated666 Dec. 2 at 3:26 PM

$ANAB Long!

0 · Reply

Reanimated666 Dec. 1 at 9:15 PM

$ANAB number 1 IBD 50

0 · Reply

StockBraker Dec. 1 at 1:25 PM

$ANAB Volume PM is negligible (11 shares) at the moment

0 · Reply

Market Cap	1.41B
Revenue (ttm)	91.28M
Net Income (ttm)	-145.23M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-159.10%
Debt to Equity Ratio	0.00

Volume	367,100
Avg Vol	534,436
Day's Range	N/A - N/A
Shares Out	27.69M
Stochastic %K	47%
Beta	0.28
Analysts	Strong Sell
Price Target	$65.09